Apr 08, 2022, 08:30
Carbiotix (publ) ("Carbiotix" or "Company") announces today that the first US patent for the production of CarbiAXOS has been allowed for issuance by the US Patent Office. This is an important milestone as the Company prepares for the launch of a CarbiAXOS nutraceutical ingredient in the US during 2022 and in 2023 begins to plan for US production activities.
Carbiotix received confirmation from the USPTO, US patent authority, that the Company’s US Patent Application no.15759228, titled: Low Molecular Weight Arabinoxylans with Branched Oligosaccharides, has been allowed for issuance. This is Carbiotix’s first patent that will be granted in the US and represents an important milestone to protect the Company’s CarbiAXOS modulator portfolio in one of the largest markets across all modulator classes (ie. food & beverage ingredients, nutraceutical ingredients, medical food co-interventions and therapeutic co-treatments).
Kristofer Cook, CEO of Carbiotix, comments
"The granting of this patent will represent a key milestone for the Company. The patent will play a pivotal role in securing our competitive position in the US market across all modulator classes and provides further confidence as we move quickly forward with the scale-up and commercialisation of CarbiAXOS. The global market for prebiotic ingredients is valued at close to 5 billion Euros and is a market where we hold a unique competitive position with our Smart Prebiotic concept. This patent will also provide protection for our CarbiAXOS medical food, which is simply a purer form of our CarbiAXOS ingredient and where the global market is valued at over 15 billion Euros. An important fact to note is that CarbiAXOS medical food also serves as the backbone for our future therapeutic candidates." (1)(2)
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 8 April 2022.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 (0)708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.